| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3296830 | Gastroenterology | 2010 | 11 Pages |
Abstract
Extending therapy with peginterferon alfa-2a/ribavirin to 72 weeks decreases the probability of relapse in patients with an EVR. If they can be maintained on extended-duration therapy, SVR rates also may improve.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Peter Ferenci, Hermann Laferl, Thomas-Matthias Scherzer, Andreas Maieron, Harald Hofer, Rudolf Stauber, Michael Gschwantler, Harald Brunner, Christoph Wenisch, Martin Bischof, Michael Strasser, Christian Datz, Wolfgang Vogel, Karin Löschenberger,